Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spikogen dose interval in COVID-19
NCT05148871Phase 3Active, not recruiting
- Sponsor
- Vaxine
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SpikoGen in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Vaxine. Primary endpoints: Spike antibody immunogenicity, Spike antibody seroconversion and 1 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05148871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148871.